This is clinical research . The test we are studying does not replace your normal check-ups, and a result is not a diagnosis. A doctor confirms any finding.
Taking part is voluntary, and you can stop anytime.
Clinical research at Dognosis
A rigorous, registere research
program.
Our studies evaluate whether a non-invasive, breath-based test can help find cancer earlier, used alongside standard care. The program is registered and ethics-approved, runs across hospitals and community screening camps in Karnataka, and is supported by a dedicated, regulated central laboratory. We work in partnership with clinicians and screening programs, and publish our findings openly.
Sponsor
Dognosis India Private Limited
Registered
CTRI/2025/07/091179
Oversight
Independent Ethics Committee
Sites
Hospitals & community camps
Central lab
CCSEA-approved, Bangalore
The studies
Two ways to take part.
Both studies test the same gentle breath test, sponsored by Dognosis and registered with the Clinical Trials Registry of India. Find the one that fits your situation. The study team confirms eligibility with you.
Recruiting
FirstAlert
Early detection & recurrence monitoring
FirstAlert tests how accurately BreathEasy detects many types of cancer, compared with standard screening and diagnosis. It runs across three groups of people over three years, to see whether a breath test can flag cancer earlier and more easily than today's methods.
Who it's for
Adults 18+ at higher risk, pre-biopsy, or post-cancer treatment
Visits
One, or several if monitoring recurrence
Where
Hospitals & screening camps, Maharashtra & Karnataka
Who can join
- Higher-risk adults coming for routine cancer screening
- People about to have a biopsy for a suspected cancer
- People who finished cancer treatment and want to watch for any return
Prospective observational · 3 years · CTRI/2025/07/091179
Recruiting
SANKET
Community screening study
SANKET is a community, camp-based study run with screening partners. It tests whether offering a breath pre-screen at camps helps find cancers at an earlier, more treatable stage than usual care. SANKET is part of the FirstAlert programme
Who it's for
Adults 45+, higher risk, no cancer symptoms
Visits
One at the camp, plus 6 & 12-month check-ins
Where
Community screening camps with our partners
Who can join
- You are 45 or older and have no cancer symptoms
- You use tobacco, or a close relative has had cancer
- You are attending a partnered screening camp
Camp-based screening study · 18 months · part of FirstAlert
Who should not take part right now, and what it costs
How the test works
From your breath to a clear result.
Our bodies release tiny scent molecules in breath. Cancer can change that scent. We pair the remarkable nose of trained dogs with technology to read the signal.
You give a breath sample
Breathe normally into a soft, single-use mask for about ten minutes. That is the whole test.
Canine olfaction reads it
At our lab, trained detection dogs with a gentle wearable sensor smell your sealed sample. You never meet the dogs.
You get a clear result
Our software turns their response into a simple result: a signal detected, or not. A signal means look closer, not a diagnosis.
After your result
What happens once we have your result.
Your sample gives a clear result: a signal detected, or not. Here is where each one leads. A signal means we look closer together, not that you have cancer.
Your breath result
A calibrated risk score: signal detected, or not detected
Carry on as usual
Most people get this result. Keep up your normal health check-ups. No extra tests are needed unless your doctor advises otherwise. If you are in a follow-up group, we will still check in at your scheduled visits.
We help you look closer
1
We confirm it
We repeat the breath test under careful conditions to be sure the signal is real.
2
We reach out
Our research team contacts you, and can arrange a repeat sample at home if that is easier for you.
3
You see a doctor
You are referred for a clinical check and the right tests, such as imaging or a biopsy, to find out what is going on.
4
A clear answer
The doctor confirms cancer or rules it out. Either way, we stay in touch and keep supporting you.
A signal is not a diagnosis. Many signals turn out not to be cancer. The aim of looking closer is simple: to find out early, either way, when there are the most options.
For hospitals & screening partners
Bring breath-based screening to your patients.
We partner with hospitals, oncology centres, and community screening programmes to add BreathEasy as a non-invasive pre-screening layer. We bring the science and the logistics; you reach more people, earlier.
Evidence-backed
A test published in the Journal of Clinical Oncology, with over 90% sensitivity including early-stage disease.
Regulatory groundwork done
CTRI-registered, ethics-approved, and tested at our CCSEA-approved central laboratory.
Evidence-backed
A test published in the Journal of Clinical Oncology, with over 90% sensitivity including early-stage disease.
Regulatory groundwork done
CTRI-registered, ethics-approved, and tested at our CCSEA-approved central laboratory.
Let's Build a Programme together
Co-authorship and shared research output, with full data transparency.
Talk to partnerships TeamYour team & your rights
Run by clinicians, with your rights first.
Experienced doctors and scientists lead the program, with independent ethics oversight. (Sponsor, registration, and lab details are in The program above.)
Dr. Sanjeev Kulgod
Chief Investigator & Medical Advisor
Dr. Shashikant Kulgod
Senior Medical Advisor
Dr. Sree Subha Ramaswamy
Lead R&D Scientist
Sahana Shanbhag
Clinical Lead
Akash Kulgod
Co-founder, Dognosis
Itamar Bitan
Co-founder, Dognosis
Your rights come first.
Taking part is completely voluntary. You can stop at any time, for any reason, without giving an explanation, and it will never affect your medical care. Your information is kept confidential and de-identified before analysis.
Evidence & recognition
Our research, in the open.
BreathEasy is built on peer-reviewed science. Here is where our work has been published and presented.
JOURNAL
Multi-cancer detection from breath using canine olfaction and a brain-computer interface Journal of Clinical Oncology · multi-centre study, 3,275 participants · 90.8% sensitivity / 91.3% specificity
Read Papers
ADD
Add your next publication or preprint here
Title · journal or repository · year · link
TALK
[Talk or poster title]
[Conference name], [City] · [Year]
POSTER
[Talk or poster title]
[Conference name], [City] · [Year]
Ready to take the next step?
Talk to us.
For interviews, imagery requests, or fact-checking, we usually reply within one business day. Founder Akash Kulgod is available for select interviews.
Participants & caregivers
Join a study
For interviews, imagery requests, or fact-checking, we usually reply within one business day. Founder Akash Kulgod is available for select interviews.
Hospitals & partners
Partner with us
Add breath-based screening to your programme, with our science and logistics behind you
